Key result
GRK2 upregulation in cardiovascular disease and obesity emerges as a potential therapeutic target.
Why the study?
GRK2 is a key signaling hub involved in heart function, metabolism, and energy homeostasis, with upregulated levels in cardiovascular pathologies and metabolic disorders, highlighting its potential as a therapeutic target.
GRK2 is highlighted as a key signaling hub and potential therapeutic target in the intersection of cardiovascular and metabolic diseases.
GRK2 upregulation links cardiac and metabolic dysfunction; hypothesis-generating for inhibition trials in HF with insulin resistance.
G protein–coupled receptor kinase 2 (GRK2) is the center of a signaling hub shared by G protein–coupled receptors and insulin networks controlling heart function and metabolism as well as global energy homeostasis . GRK2 levels and activity are upregulated in the heart and in tissues that are the key to metabolic control during cardiovascular pathologies and in obesity and insulin resistance–related contexts, which are frequent comorbidities in the clinical practice, pointing to this protein as a potentially relevant therapeutic target. Recent research is unveiling the signals and mechanisms involved in the modulation of GRK2 expression and functionality in these physiopathological contexts and disclosing how altered GRK2 levels contribute to disease progression by modulating the functionality and cross talk of cardiac and metabolically relevant tissues.
No takes yet. Share an insight, caveat, or question.
Arcones et al. (2020) conducted a review in Metabolic and cardiovascular diseases. G protein-coupled receptor kinase 2 (GRK2) was evaluated. G protein-coupled receptor kinase 2 (GRK2) levels and activity are upregulated during cardiovascular pathologies, obesity, and insulin resistance, making it a potentially relevant therapeutic target.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: